All regulatory updates
718 results found
European Commission publishes updated RoHS exemptions tracker (“Exemptions list: Validity and rolling plan Feb 2026”)
The European Commission posted an updated RoHS exemptions tracking spreadsheet (“Exemptions list: Validity and rolling plan Feb 2026”) on 31 March 2026, linked from the RoHS Directive implementation pages. While not a legal amendment by itself, this Commission-published tracker is compliance-relevant because it consolidates current exemption validity periods and the Commission’s rolling plan, supporting manufacturers’ planning for exemption renewals/expirations and transition timing under RoHS Annex III/IV processes.
Louisiana HB 152 (2026 Regular Session) proposes adding new opiate entries to Schedule I of the UCDSL
Louisiana HB 152 (2026 Regular Session) is active legislative activity proposing to add new entries (opiates) to Schedule I (R.S. 40:964) of the Uniform Controlled Dangerous Substances Law, with new Schedule I entries referenced as R.S. 40:964(A)(108) through (120) in the research summary. Compliance impact: if enacted, affected substances would become Schedule I controlled substances under Louisiana law, impacting prohibited acts, enforcement exposure, and compliance programs for any entities that may handle or encounter these substances (e.g., forensic labs, healthcare/pharmacy, law enforcement evidence handling). Specific substance names and final effective date should be confirmed from the bill text/enrolled act upon enactment.
Louisiana HB 152 (2026 Regular Session) proposes adding specified substances to Schedule I under R.S. 40:964
House Bill 152 (2026 Regular Session) proposes amendments to Louisiana’s Uniform Controlled Dangerous Substances Law by adding certain substances to Schedule I in R.S. 40:964. The Senate Order of the Day materials list HB 152 with the caption 'Adds certain substances to the Uniform Controlled Dangerous Substances Law,' and the bill text PDF is cited as proposing new Schedule I entries. Compliance teams for controlled substance handling (manufacturers/distributors/pharmacies and related compliance programs) should monitor this bill because enactment would expand Schedule I controls for the newly listed substances, impacting inventory controls, security, recordkeeping, and potential criminal exposure for possession/distribution.
European Commission publishes PPWR implementation guidance (Commission Notice/guidance document and supporting materials)
The European Commission issued an official guidance package to support implementation of the Packaging and Packaging Waste Regulation (EU) 2025/40 (PPWR). The materials (press communication plus the Commission Communication approving the draft Notice and annexed guidance text, and the guidance landing page) provide interpretive clarifications on PPWR concepts and obligations that affect compliance scoping and operational readiness—e.g., what qualifies as “packaging,” delineation of economic operator roles (manufacturer/producer), interpretation of certain restrictions (including for specific packaging types), and how selected provisions interface with EPR and deposit/return system obligations. Compliance teams can use this guidance to refine internal PPWR applicability determinations, role mapping, and evidence/recordkeeping expectations while tracking anticipated delegated/implementing acts referenced by the Commission.
EPA proposes reporting deadline extension for TSCA 8(d) Health and Safety Data Reporting rule (16 substances)
EPA proposed to extend the reporting deadline for the TSCA Section 8(d) Health and Safety Data Reporting rule covering 16 chemical substances. Compliance teams responsible for submitting unpublished health and safety studies and related information under TSCA 8(d) should review the proposed extension and adjust internal data-collection and submission timelines accordingly.
HHS issues HHSAR Class Deviation 2026-02 Amendment 1 updating Part 335/352 clauses for human subjects research and live vertebrate animal requirements
HHS published HHSAR Class Deviation 2026-02 Amendment 1, effective immediately upon signature, updating deviated HHSAR text for Part 335 (Research and Development Contracting) and associated Part 352 provisions/clauses. The deviation addresses solicitation/contract clause requirements and compliance artifacts for acquisitions involving human subjects research (e.g., Federalwide Assurance and IRB-related requirements) and the use of live vertebrate animals (e.g., Animal Welfare Assurance and IACUC-related requirements), including instructions on inclusion in solicitations/contracts/orders and treatment of open solicitations/existing contracts. Compliance teams supporting vendors/contractors performing HHS R&D work should review updated clause flowdowns and required assurances/certifications for prime and subcontractor arrangements.
Stockholm Convention Secretariat opens comment period on draft review of specific exemption for PFOI→PFOB (pharmaceuticals)
The Stockholm Convention Secretariat published an invitation for Parties and stakeholders to submit comments on a draft report reviewing the specific exemption for the use of perfluorooctyl iodide (PFOI) to produce perfluorooctyl bromide (PFOB) for pharmaceutical products. This consultation may inform whether the exemption is continued, modified, or allowed to expire, which is relevant for pharmaceutical supply chains relying on this specific exemption pathway.
Secretariat invites comments on draft review of PFOI→PFOB (pharmaceuticals) specific exemption (deadline 22 May 2026)
The Stockholm Convention Secretariat issued an invitation to submit comments on a draft report reviewing the specific exemption for the use of perfluorooctyl iodide (PFOI) to produce perfluorooctyl bromide (PFOB) for the production of pharmaceutical products. The communications listing specifies a comment deadline of 22 May 2026. Compliance teams should monitor this exemption review because the outcome can change the continued availability/conditions of the exemption and may trigger updates to national implementation measures for affected pharmaceutical supply chains.
Stockholm Convention Secretariat opens call for comments on draft review of PFOI→PFOB (pharmaceuticals) specific exemption
The Stockholm Convention Secretariat posted an invitation for Parties and stakeholders to submit comments on a draft report reviewing the specific exemption for use of perfluorooctyl iodide (PFOI) to produce perfluorooctyl bromide (PFOB) for the purpose of producing pharmaceutical products. Compliance teams in affected supply chains (fluorochemicals and pharma intermediates) should review the draft review report and submit technical/economic information within the stated comment window, as outcomes can inform whether the exemption is continued, modified, or allowed to expire in future COP decisions.
Secretariat invitation for comments on draft review of the PFOI→PFOB (pharmaceuticals) specific exemption (deadline 22 May 2026)
The Stockholm Convention Secretariat issued a communication inviting Parties and observers to submit comments on a draft report reviewing the specific exemption for the use of perfluorooctyl iodide (PFOI) to produce perfluorooctyl bromide (PFOB) for pharmaceutical products. The communication sets a comment submission deadline of 22 May 2026. This matters for compliance because outcomes of exemption reviews can change conditions, scope, or continuation/expiry of permitted uses for Annex-listed POPs and may require companies supporting registered uses to adjust sourcing, product formulations, or documentation supporting continued lawful use in Parties relying on the exemption.
Secretariat invites comments on draft review of specific exemption for perfluorooctyl iodide (PFOI) used to produce perfluorooctyl bromide (PFOB) for pharmaceuticals
The Stockholm Convention Secretariat issued a communication inviting Parties and observers to submit comments on a draft report reviewing the specific exemption covering the use of perfluorooctyl iodide (PFOI) for the production of perfluorooctyl bromide (PFOB) for the purpose of producing pharmaceutical products. The communication sets a comment deadline of 22 May 2026. Compliance teams supporting pharmaceutical supply chains and Parties relying on this exemption should monitor the review outcome, as it may lead to changes to the scope, conditions, or continuation/expiry of the exemption under the Convention’s register of specific exemptions.
Secretariat opens comment period on draft report reviewing specific exemption for PFOI use to produce PFOB for pharmaceuticals
The Stockholm Convention Secretariat opened an invitation for Parties/observers to submit comments on a draft report reviewing the specific exemption for the use of perfluorooctyl iodide (PFOI) to produce perfluorooctyl bromide (PFOB) for pharmaceutical products. This is a POPs Convention process step that may affect continuation, modification, or expiration of the exemption and therefore future availability of this exemption pathway for regulated entities and supply chains.
FMCSA broker & freight forwarder financial responsibility compliance changes effective Jan 16, 2026 (insurance/financial responsibility filing requirements)
FMCSA’s official Insurance Filing Requirements page highlights that, effective January 16, 2026, brokers, freight forwarders, and financial responsibility providers must comply with the Broker and Freight Forwarder Financial Responsibility rule requirements. For organizations that treat freight brokers/forwarders as vendors, this functions as a gating compliance requirement for onboarding and ongoing qualification because vendor eligibility depends on meeting FMCSA financial responsibility/insurance filing obligations. The same FMCSA page also notes an implementation/system transition affecting insurance filing processes (limited access to the new registration system, Motus, starting in December 2025).
ECHA launches 60-day consultation on SEAC draft opinion for EU-wide PFAS REACH restriction (universal PFAS proposal)
ECHA materials for the EU-wide ("universal") PFAS restriction under REACH indicate that consultation on SEAC’s draft opinion opened on 26 March 2026 and runs for 60 calendar days. This is a key milestone in the restriction process and a near-term action point for companies and associations to submit technical and socio-economic information (uses, alternatives, costs, emissions) relevant to potential restriction conditions and transition periods across affected sectors.
ECHA opens 60-day consultation on SEAC draft opinion for EU-wide PFAS restriction; RAC opinion adopted
ECHA opened a 60-day stakeholder consultation on SEAC’s draft opinion related to the proposed EU-wide REACH restriction on PFAS (universal PFAS proposal). ECHA communications also confirm RAC has adopted its opinion on the restriction proposal and that the committees support an EU-wide restriction with targeted derogations and risk-management measures for derogated uses. Compliance teams should use the open consultation window to submit technical and socioeconomic evidence, especially regarding use essentiality, alternatives, transition timelines, and emission minimisation/management measures that could become conditions of any future restriction.
EPA proposes extending certain compliance dates in TSCA Section 6 risk management rules for perchloroethylene (PCE) and carbon tetrachloride (CTC)
EPA announced a proposal to extend certain compliance dates in the final TSCA Section 6 risk management rules for perchloroethylene (PCE) and carbon tetrachloride (CTC) to improve practical implementation (including Workplace Chemical Protection Program-related timelines). Until any amendments are finalized, currently-effective compliance dates remain in effect. EPA is seeking public comment via docket EPA-HQ-OPPT-2026-0992 on Regulations.gov.
EPA proposes extending compliance dates in TSCA Section 6 risk management rules for perchloroethylene (PCE) and carbon tetrachloride (CTC)
EPA released a proposal to extend certain compliance dates in the final TSCA Section 6 risk management rules for perchloroethylene (PCE) and carbon tetrachloride (CTC) while EPA works on further rule revisions. EPA states it is not revisiting the underlying TSCA unreasonable risk determinations and that protections are not being weakened. EPA indicates a 30-day public comment period will run upon Federal Register publication and points stakeholders to the rulemaking docket via Regulations.gov, which compliance teams should monitor for the Federal Register notice, specific extended dates, and applicability details.
NIOSH solicits nominations for Mine Safety and Health Research Advisory Committee (MSHRAC)
CDC/NIOSH published a Federal Register notice soliciting nominations to fill vacancies on the Mine Safety and Health Research Advisory Committee (MSHRAC). This is an administrative/governance action (not a new employer compliance requirement), but it is a formal NIOSH process update that stakeholders may want to track and respond to. The notice specifies a nominations deadline of April 22, 2026.
EPA proposes extending certain compliance dates in TSCA §6 risk management rules for perchloroethylene (PCE) and carbon tetrachloride (CTC)
EPA announced a proposal to extend certain compliance dates in the final TSCA §6 risk management rules for perchloroethylene (PCE) and carbon tetrachloride (CTC), stating it is working on revisions intended to make the rules more practical and implementable. Until EPA completes rulemaking, existing compliance dates remain in effect. Compliance teams should monitor the Federal Register publication and the associated comment process once opened.
Member State dossier submitted proposing MCCP restriction under RoHS Annex II mechanism (Article 6(1))
An EC-hosted RoHS Annex II restriction dossier proposes adding Medium-Chained Chlorinated Paraffins (MCCPs) as a restricted substance for electrical and electronic equipment under the RoHS Article 6(1) process (potential future Annex II amendment). This is a proposal/supporting dossier rather than a binding RoHS legal change; however, it signals a potential future substance restriction topic that compliance teams may want to monitor for portfolio and material-risk assessment.